Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to develop targeted cancer therapies, announced that management will present at the ThinkEquity Conference on October 15, 2026, at 3:30 p.m. ET. The event will take place at the Mandarin Oriental in New York City, with a live webcast available for remote attendees. Company executives will also hold one-on-one investor meetings throughout the conference.
The presentation comes as Lantern Pharma seeks to differentiate itself in the competitive oncology space through its proprietary RADR® AI and machine-learning platform. RADR integrates large-scale genomic and biological data to identify patients most likely to respond to specific therapies, potentially transforming the cost, pace, and precision of drug development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with a central-nervous-system-focused subsidiary, Starlight Therapeutics, and an AI subsidiary, Open-Medicine AI.
Investor interest in AI-driven biotech has surged in recent years, as companies aim to reduce the high failure rates and lengthy timelines associated with traditional drug discovery. Lantern Pharma’s approach could lead to more efficient clinical trials by matching therapies to biomarker-defined patient populations. The ThinkEquity Conference provides a platform for the company to communicate its progress and strategic vision to institutional and individual investors.
For those unable to attend in person, the live webcast will offer real-time access to the presentation. Additional details are available in the full press release at https://ibn.fm/hmTGq. Investors can also find ongoing updates and news in the company’s newsroom at https://ibn.fm/LTRN.
The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication and editorial syndication to 5,000+ outlets, along with social media distribution and other corporate communications solutions. The full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
Lantern Pharma’s presentation at the ThinkEquity Conference is significant because it offers a window into how AI is being harnessed to streamline oncology drug development. If successful, the company’s RADR platform could help bring new cancer therapies to market faster and more cost-effectively, ultimately benefiting patients and investors alike. The conference appearance also signals Lantern Pharma’s continued engagement with the investment community as it advances its pipeline and seeks to create value.
